By providing an overview of the mitochondrial dysfunction in SMA, our intention is to guide molecular mechanistic understanding and aid translational targeting of mitochondria, which offer many routes for complementary therapeutic interventions to current SMN-replacement therapies. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.